Novo Nordisk (NOVO) is petitioning the FDA to exclude its diabetes drug liraglutide, also known as Victoza, from a list of ...

Novo Nordisk retains a strong market position in a high-growth industry, with P/E multiples poised to expand. See why NVO ...

Novo Nordisk ADR (NYSE: NVO) currently trades at $89 per share, nearly 40% below its peak level of over $145 seen in June of ...

What happened with Novo Nordisk stock? On Dec. 20, Novo announced results from a phase 3 clinical trial surrounding one of ...

Pharmaceutical stalwart Novo Nordisk (NVO) can’t seem to get anything good going these days. As TipRanks’ Vince Condarcuri ...

Loomis Sayles, an investment management company, released its “International Growth Fund” third quarter 2024 investor letter.

Confluence Investment Management LLC increased its stake in Novo Nordisk A/S (NYSE:NVO – Free Report) by 2.2% during the ...

Buying $1000 In NVO: If an investor had bought $1000 of NVO stock 10 years ago, it would be worth $4,177.57 today based on a ...

We came across a bullish thesis on Novo Nordisk A/S (NYSE:NVO) on Kontra Investments’ Substack by Kontra. In this article, we ...

The general mood among these heavyweight investors is divided, with 50% leaning bullish and 31% bearish. Among these notable ...

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...